Publication related to RSI or an RSI staff member
Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis.
Authors
- Alami, Abdallah, Alami A, School of Mathematics and Statistics, Faculty of Science, Carleton University, Ottawa, Ontario, Canada abdallahalami@cmail.carleton.ca.
- Krewski, Daniel, Krewski D, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; Risk Sciences International, Ottawa, Ontario, Canada.
- Farhat, Nawal, Farhat N, School of Mathematics and Statistics, Faculty of Science, Carleton University, Ottawa, Ontario, Canada.
- Mattison, Donald, Mattison D, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; Risk Sciences International, Ottawa, Ontario, Canada.; Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.
- Wilson, Kumanan, Wilson K, Bruyère Research Institute, University of Ottawa, Ottawa, Ontario, Canada.; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- Gravel, Christopher A, Gravel CA, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada.; Department of Mathematics and Statistics, University of Ottawa, Ottawa, Ontario, Canada.
- Farrell, Patrick J, Farrell PJ, School of Mathematics and Statistics, Faculty of Science, Carleton University, Ottawa, Ontario, Canada.
- Crispo, James A G, Crispo JAG, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.; Division of Human Sciences, NOSM University, Sudbury, Ontario, Canada.
- Haddad, Nisrine, Haddad N, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- Perez-Lloret, Santiago, Perez-Lloret S, Consejo Nacional de Investigaciones CientÃficas y Técnicas (CONICET), Buenos Aires, Argentina.; Observatorio de Salud Pública, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina.; Department of Physiology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
- Villeneuve, Paul J, Villeneuve PJ, Department of Neurosciences, Faculty of Science, Carleton University, Ottawa, Ontario, Canada.
YEAR OF PUBLICATION: 2023
SOURCE: BMJ Open. 2023 Jun 20;13(6):e065687. doi: 10.1136/bmjopen-2022-065687.
JOURNAL TITLE ABBREVIATION: BMJ Open
JOURNAL TITLE: BMJ open
ISSN: 2044-6055 (Electronic) 2044-6055 (Linking)
VOLUME: 13
ISSUE: 6
PAGES: e065687
PLACE OF PUBLICATION: England
ABSTRACT:
OBJECTIVE: To summarise the available evidence on the risk of myocarditis and/or pericarditis following mRNA COVID-19 vaccination, compared with the risk among unvaccinated individuals in the absence of COVID-19 infection. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic databases (Medline, Embase, Web of Science and WHO Global Literature on Coronavirus Disease), preprint repositories (medRxiv and bioRxiv), reference lists and grey literature were searched from 1 December 2020 until 31 October 2022. STUDY SELECTION: Epidemiological studies of individuals of any age who received at least one dose of an mRNA COVID-19 vaccine, reported a risk of myo/pericarditis and compared the risk of myo/pericarditis to individuals who did not receive any dose of an mRNA COVID-19 vaccine. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently conducted screening and data extraction. The rate of myo/pericarditis among vaccinated and unvaccinated groups was recorded, and the rate ratios were calculated. Additionally, the total number of individuals, case ascertainment criteria, percentage of males and history of SARS-CoV-2 infection were extracted for each study. Meta-analysis was done using a random-effects model. RESULTS: Seven studies met the inclusion criteria, of which six were included in the quantitative synthesis. Our meta-analysis indicates that within 30-day follow-up period, vaccinated individuals were twice as likely to develop myo/pericarditis in the absence of SARS-CoV-2 infection compared to unvaccinated individuals, with a rate ratio of 2.05 (95% CI 1.49-2.82). CONCLUSION: Although the absolute number of observed myo/pericarditis cases remains quite low, a higher risk was detected in those who received mRNA COVID-19 vaccinations compared with unvaccinated individuals in the absence of SARS-CoV-2 infection. Given the effectiveness of mRNA COVID-19 vaccines in preventing severe illnesses, hospitalisations and deaths, future research should focus on accurately determining the rates of myo/pericarditis linked to mRNA COVID-19 vaccines, understanding the biological mechanisms behind these rare cardiac events and identifying those most at risk.
OBJECTIVE: To summarise the available evidence on the risk of myocarditis and/or pericarditis following mRNA COVID-19 vaccination, compared with the risk among unvaccinated individuals in the absence of COVID-19 infection. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic databases (Medline, Embase, Web of Science and WHO Global Literature on Coronavirus Disease), preprint repositories (medRxiv and bioRxiv), reference lists and grey literature were searched from 1 December 2020 until 31 October 2022. STUDY SELECTION: Epidemiological studies of individuals of any age who received at least one dose of an mRNA COVID-19 vaccine, reported a risk of myo/pericarditis and compared the risk of myo/pericarditis to individuals who did not receive any dose of an mRNA COVID-19 vaccine. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently conducted screening and data extraction. The rate of myo/pericarditis among vaccinated and unvaccinated groups was recorded, and the rate ratios were calculated. Additionally, the total number of individuals, case ascertainment criteria, percentage of males and history of SARS-CoV-2 infection were extracted for each study. Meta-analysis was done using a random-effects model. RESULTS: Seven studies met the inclusion criteria, of which six were included in the quantitative synthesis. Our meta-analysis indicates that within 30-day follow-up period, vaccinated individuals were twice as likely to develop myo/pericarditis in the absence of SARS-CoV-2 infection compared to unvaccinated individuals, with a rate ratio of 2.05 (95% CI 1.49-2.82). CONCLUSION: Although the absolute number of observed myo/pericarditis cases remains quite low, a higher risk was detected in those who received mRNA COVID-19 vaccinations compared with unvaccinated individuals in the absence of SARS-CoV-2 infection. Given the effectiveness of mRNA COVID-19 vaccines in preventing severe illnesses, hospitalisations and deaths, future research should focus on accurately determining the rates of myo/pericarditis linked to mRNA COVID-19 vaccines, understanding the biological mechanisms behind these rare cardiac events and identifying those most at risk.
COPYRIGHT INFORMATION: (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No||commercial re-use. See rights and permissions. Published by BMJ.
LANGUAGE: eng
DATE OF PUBLICATION: 2023 Jun 20
DATE OF ELECTRONIC PUBLICATION: 20230620
DATE COMPLETED: 20230622
DATE REVISED: 20230704
MESH DATE: 2023/06/22 06:42
EDAT: 2023/06/21 01:07
STATUS: MEDLINE
PUBLICATION STATUS: epublish
LOCATION IDENTIFIER: 10.1136/bmjopen-2022-065687 [doi] e065687
OWNER: NLM
Related RSI Experts
Chief Medical Officer, Senior Vice-President
Dr. Donald Mattison joined Risk Sciences International (RSI) in 2012 as Senior Vice-President and Chief Medical Officer, bringing with him a distinguished career spanning public health, clinical medicine, toxicology, and academic leadership. His appointment significantly strengthened RSI’s capacity to deliver...
Chief Risk Scientist
Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...